Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02149901 · ClinicalTrials.gov registry record · Early Phase 1
Water and Sudafed in Autonomic Failure
A Early Phase 1 study, sponsored by Vanderbilt University.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 35
- Enrollment target
NCT02149901 is a Early Phase 1 study that was terminated before completion, run by Vanderbilt University. The registered enrollment target is 35 participants.
The verdict
NCT02149901, a Early Phase 1 study, was terminated before completion, sponsored by Vanderbilt University.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
The specific aim of this study is to determine whether water ingestion potentiates the pressor response to pseudoephedrine in patients with primary disorders of autonomic failure. The study design will enable us to also evaluate the pressor response to water alone and to pseudoephedrine alone. In a secondary analysis, we will compare the results in patients with two autonomic disorders, pure autonomic failure (PAF) and multiple system atrophy (MSA). We hypothesize that drinking water following a dose of pseudoephedrine will lead to a greater increase in blood pressure than pseudoephedrine alone.
Interventions
- DRUG Pseudoephedrine + 480 ml water
- DRUG Pseudoephedrine + 50 ml water
- OTHER Placebo + 480 ml water (optional)
- OTHER Placebo + 50 ml water (optional)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2014-10 |
| Est. Completion | 2020-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02149901
The ClinicalTrials.gov registry entry for NCT02149901 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Pseudoephedrine + 480 ml water is the first listed.
NCT02149901 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02149901 about?
NCT02149901 is a clinical study titled "Water and Sudafed in Autonomic Failure". The specific aim of this study is to determine whether water ingestion potentiates the pressor response to pseudoephedrine in patients with primary disorders of autonomic failure. The study design will enable us to also evaluate the pressor response to water alone and to pseudoephedrine alone. In a ...
What is the current status of trial NCT02149901?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 35 participants. The study started on 2014-10. Estimated completion is 2020-12.
What interventions are being tested in trial NCT02149901?
The interventions under investigation include: Pseudoephedrine + 480 ml water (DRUG), Pseudoephedrine + 50 ml water (DRUG), Placebo + 480 ml water (optional) (OTHER), Placebo + 50 ml water (optional) (OTHER).
Who is sponsoring clinical trial NCT02149901?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.